DANICOPAN | DANICOPAN | ATC L04AJ09
IMMUNOSUPPRESSANTS COMPLEMENT FACTOR D INHIBITOR TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PREVENTS THE CLEAVAGE OF COMPLEMENT FACTOR B INTO THE BA AND BB FRAGMENTS | ORAL | Cmax 1.14 MICROMOLAR Tmax 3.7 HOUR VD 395 LITER PPB 92.9 PERCENT Cl 63 LITER / HOUR HT 7.9 HOUR SOLUBILITY INSOLUBLE FROM PH 4 TO PH 7 | COMPLEMENT FACTOR D | - more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |